Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

Inclusion Criteria:

• Newly diagnosed or relapsing ANCA-associated vasculitis, GPA and MPA subtypesconsistent with the 2022 ACR/EULAR classification criteria for GPA and MPA for whomtreatment with rituximab or cyclophosphamide is considered.

• Positive test for antibodies to either PR3-ANCA or MPO-ANCA at Screening or in thepast by a quantitative assay (for example, ELISA, bead assay).

• At least one major item, or at least 3 minor items, or at least 2 renal items in theBVAS.

Exclusion Criteria:

• Other systemic diseases that, in the judgment of the Investigator, constitute theprimary illness, including but not limited to: eosinophilic granulomatosis withpolyangiitis (EGPA), systemic lupus erythematosus, IgA nephropathy and/or IgAassociated vasculitis with or without Henoch-Schonlein purpura, rheumatoidvasculitis, Sjogren's syndrome, anti-GBM disease, cryoglobulinemic vasculitis,autoimmune hemolytic anemia, or mixed connective tissue disease.

• Alveolar hemorrhage requiring invasive pulmonary ventilation support at Screening.

• Any diseases or conditions that, in the judgment of the Investigator, present asubstantial clinical risk to participate in this study.

• For patients with a previous diagnosis of CKD, patients known to have a stable eGFRfor greater than 3 months prior to Screening and a decline less than 25% of previouseGFR at Screening will be excluded.